Geode Capital Management LLC raised its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 86.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 553,247 shares of the company's stock after purchasing an additional 256,635 shares during the quarter. Geode Capital Management LLC owned about 1.67% of Lexeo Therapeutics worth $5,003,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. BNP Paribas Financial Markets boosted its stake in Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after purchasing an additional 3,591 shares during the period. Values First Advisors Inc. bought a new position in shares of Lexeo Therapeutics in the 3rd quarter valued at approximately $67,000. MetLife Investment Management LLC increased its stake in shares of Lexeo Therapeutics by 121.5% in the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company's stock worth $129,000 after purchasing an additional 7,803 shares during the period. Rhumbline Advisers lifted its position in shares of Lexeo Therapeutics by 37.3% during the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company's stock worth $214,000 after purchasing an additional 3,627 shares during the last quarter. Finally, PDT Partners LLC bought a new stake in shares of Lexeo Therapeutics in the third quarter valued at approximately $241,000. Institutional investors own 60.67% of the company's stock.
Lexeo Therapeutics Stock Up 9.3 %
Shares of NASDAQ:LXEO traded up $0.62 during midday trading on Friday, hitting $7.29. The stock had a trading volume of 227,486 shares, compared to its average volume of 200,743. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The business's 50-day simple moving average is $7.31 and its 200-day simple moving average is $10.18. The company has a market cap of $241.05 million, a P/E ratio of -2.31 and a beta of 3.08. Lexeo Therapeutics, Inc. has a 12 month low of $5.77 and a 12 month high of $22.33.
Insider Activity
In related news, CEO Richard Nolan Townsend sold 5,000 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the sale, the chief executive officer now owns 120,695 shares in the company, valued at approximately $977,629.50. This trade represents a 3.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 10,000 shares of company stock valued at $80,550 over the last ninety days. 4.50% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on LXEO. Chardan Capital boosted their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. HC Wainwright raised their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, November 14th. Finally, Leerink Partners reduced their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Buy" and a consensus target price of $23.80.
Check Out Our Latest Research Report on LXEO
About Lexeo Therapeutics
(
Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Featured Stories
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
